Solid Biosciences Inc. (SLDB)

CIK 0001707502 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q2-2026 —
Q1-2026 —
Latest FY-2025 8-K (2026-03-06)
Q3-2025 8-K (2025-11-03) · 99.1 · 99.2
Q2-2025 —
Q1-2025 —
FY-2024 8-K (2025-02-18) · 99.1
Q3-2024 —
Q2-2024 —
Q1-2024 —
FY-2023 8-K (2024-01-08) · 99.1 · 99.2
Q3-2023 —

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Document and Entity Information
Statements
Consolidated Balance Sheets
Consolidated Balance Sheets (P)
Consolidated Statements of Operations
Consolidated Statements of Comprehensive Loss
Consolidated Statements of Changes In Stockholders' Equity
Consolidated Statements of Stockholders' Equity
—
Consolidated Statements of Changes In Stockholders' Equity (P)
Consolidated Statements of Stockholders' Equity (P)
—
Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows (P)
Notes
Accrued Expenses
—
Accrued Expenses and Other Current Liabilities
Acquisition
Available-for-sale Securities
Award Timing Disclosure
—
Collaborations
—
Commitments and Contingencies
Cybersecurity Risk Management, Strategy, and Governance
—
Defined Contribution Plan
—
Equity-based Compensation
Fa212 Asset Acquisition
Fair Value Measurements
Fair Value of Financial Assets and Liabilities
Income Taxes
Insider Trading Arrangements
Insider Trading Policies and Procedures
—
Leases
License Agreements
—
License and Research Agreements
—
Nature of The Business
—
Nature of The Business and Basis of Presentation
Net Loss Per Share
Outlicensing Agreements
—
Prepaid Expenses and Other Current Assets
Property and Equipment
Property and Equipment, Net
—
Restructuring
Segment Reporting
Stockholders' Equity
—
Subsequent Events
Summary of Significant Accounting Policies